Get the Stockscreener App
19.03
4.62%
0.84
After Hours:
19.29
0.26
+1.37%
Summit Therapeutics Inc stock is traded at $19.03, with a volume of 2.56M.
It is up +4.62% in the last 24 hours and up +2.48% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$18.19
Open:
$18.52
24h Volume:
2.56M
Relative Volume:
1.20
Market Cap:
$14.03B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-79.29
EPS:
-0.24
Net Cash Flow:
$-113.02M
1W Performance:
+6.61%
1M Performance:
+2.48%
6M Performance:
+104.40%
1Y Performance:
+468.06%
1-Day Range:
$18.33
$19.39
1-Week Range:
$16.46
$19.39
52-Week Range:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.03 | 14.03B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Here’s Why Analysts Are Bullish on Summit Therapeutics Inc. (SMMT) - Insider Monkey
Long Term Trading Analysis for (SMMT) - Stock Traders Daily
Is Summit Therapeutics (SMMT) the Best Russell 2000 Stock to Invest in According to Analysts? - MSN
Summit Therapeutics (SMMT) Stock Price, News & Analysis - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherWhat's Next? - MarketBeat
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade) - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.3%Here's What Happened - MarketBeat
Looking At Summit Therapeutics's Recent Unusual Options Activity - Benzinga
24,879 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Bought by SeaCrest Wealth Management LLC - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics (SMMT) Stock Surge Driven by Promising Drug Trials - GuruFocus.com
Why Summit Therapeutics Rocketed 584% in 2024 - MSN
Summit Therapeutics Highlights Success at Healthcare Conference - TipRanks
Summit Therapeutics (NASDAQ:SMMT) Stock Quotes, Forecast and News Summary - Benzinga
(SMMT) Technical Data - Stock Traders Daily
Summit Therapeutics (NASDAQ:SMMT) Shares Up 3.3%Should You Buy? - MarketBeat
Merck rival Summit draws new buy from Truist on deal prospects - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Truist Financial - MarketBeat
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
SA Asks: Which biotechs are most likely to be acquired near-term? - Seeking Alpha
The Play On Summit Therapeutics (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.33 Consensus PT from Analysts - MarketBeat
Prediction: These 3 Healthcare Stocks Will Soar in 2025 - Yahoo Finance
Why Is Summit Therapeutics Inc. (SMMT) Among the Best Multibagger Stocks to Buy Right Now? - Insider Monkey
12 Best Multibagger Stocks to Buy Right Now - Insider Monkey
Insider Stock Buying Reaches US$78.8m On Summit Therapeutics - Simply Wall St
3 Stocks That Could Be Monster Winners in 2025 - Yahoo Finance
Here are Morgan Stanley’s key oncology catalysts for 2025 - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.2%Here's Why - MarketBeat
103,276 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Bought by Franklin Resources Inc. - MarketBeat
10 Best Performing Biotech Stocks in 2024 - Insider Monkey
Is Summit Therapeutics Inc. (SMMT) the Best Performing Biotech Stock in 2024? - Insider Monkey
Geode Capital Management LLC Increases Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Barclays PLC Sells 137,195 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - MSN
Why These 10 Stocks Jumped Yesterday - Insider Monkey
Where Will Summit Therapeutics Be in 5 Years? - Yahoo Finance
3 Stocks That Could Turn $1,000 into $5,000 by 2030 - The Motley Fool
Wellington Management Group LLP Sells 223,964 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading Up 6.8%Should You Buy? - MarketBeat
(SMMT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Has Summit Therapeutics Stock Already Peaked? - AOL
State Street Corp Sells 654,623 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday - MSN
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street - Yahoo! Voices
Virtu Financial LLC Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Wells Fargo Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - MSN
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
2.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):